First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU, and the EMA has started its review. The six-valent ...

Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

June and July delivered a busy stretch of leadership moves across pharma and biotech. From major R&D appointments at large drugmakers to a wave of CEO, CMO, and commercial hires across emerging ...

ADC Therapeutics' chances of upgrading its accelerated approval for diffuse large B-cell lymphoma therapy Zynlonta to a full approval have taken a knock. In its second-quarter res ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...

Less than two years after buying Chinese biotech Gracell for its cell therapy platform, AstraZeneca has reported encouraging clinical results with the lead CAR-T from the deal, GC012F (now AZD0120), ...

AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will persuade the FDA to approve the oral selective oestrogen receptor degrader (SERD ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...

AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impinging patient access to new therapies. That is the finding of a survey by Swiss ...